



(12) Translation of
European patent specification

(11) NO/EP 3321270 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 498/14 (2006.01) A61K 45/06 (2006.01)
A61K 9/20 (2006.01) A61P 31/00 (2006.01)
A61K 31/513 (2006.01) A61P 31/18 (2006.01)
A61K 31/553 (2006.01) A61P 43/00 (2006.01)
A61K 31/675 (2006.01) C07D 498/18 (2006.01)
A61K 31/683 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2025.03.31
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.12.04
(86)	European Application Nr.	17204116.2
(86)	European Filing Date	2015.06.19
(87)	The European Application's Publication Date	2018.05.16
(30)	Priority	2014.06.20, US, 201462015245 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated validation states:	MA
(62)	Divided application	EP3157932, 2015.06.19
(73)	Proprietor	Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	CARRA, Ernest A., c/o Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404, USA CHEN, Irene, c/o Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404, USA ZIA, Vahid, c/o Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, CA 94404, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	SODIUM (2R, 5S, 13AR)-7, 9-DIOXO-10- ((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2, 3, 4, 5, 7, 9, 13,13A-OCTAHYDRO-2,5-METHANOPYRIDO [1',2':4.5] PYRAZINO [2, 1-B] OXAZEPIN-8-OLATE
(56)	References Cited:	EP-A1- 2 465 580 WO-A1-2014/100323

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Krystallinsk forbindelse med formel II:



5

2. Forbindelsen ifølge krav 1, **karakterisert ved** et røntgenpulverdiffraksjons- (XRPD)-mønster med topper på ca. 5,5°, 16,1° og 23,3° 2-θ ± 0,2° 2-θ.

10 3. Forbindelsen ifølge krav 2, hvori røntgenpulverdiffraksjons- (XRPD)-mønsteret har ytterligere topper på ca. 22,1° og 28,5° 2-θ ± 0,2° 2-θ.

4. Forbindelsen ifølge krav 3, hvori røntgenpulverdiffraksjons- (XRPD)-mønsteret har ytterligere topper på ca. 22,5 og 19,5° 2-θ ± 0,2° 2-θ.

15 5. Forbindelsen ifølge krav 4, hvori røntgenpulverdiffraksjons- (XRPD)-mønsteret har ytterligere topper på ca. 26,6° og 17,9° 2-θ ± 0,2° 2-θ.